Other
12 Authors
- Retnakaran R,
- Gaisano HY,
- Wang L,
- Schroer SA,
- Liu Y,
- Choi D,
- Zhang Y,
- Woo M,
- Wu X,
- Wu H,
- Lu SY,
- Wagner KU
| First Author | Choi D | Year | 2010 |
| Journal | J Exp Med | Volume | 207 |
| Issue | 13 | Pages | 2831-42 |
| PubMed ID | 21149549 | Mgi Jnum | J:176862 |
| Mgi Id | MGI:5292831 | Doi | 10.1084/jem.20100665 |
| Citation | Choi D, et al. (2010) Erythropoietin protects against diabetes through direct effects on pancreatic beta cells. J Exp Med 207(13):2831-42 |
| abstractText | A common feature among all forms of diabetes mellitus is a functional beta-cell mass insufficient to maintain euglycemia; therefore, the promotion of beta-cell growth and survival is a fundamental goal for diabetes prevention and treatment. Evidence has suggested that erythropoietin (EPO) exerts cytoprotective effects on nonerythroid cells. However, the influence of EPO on pancreatic beta cells and diabetes has not been evaluated to date. In this study, we report that recombinant human EPO treatment can protect against diabetes development in streptozotocin-induced and db/db mouse models of type 1 and type 2 diabetes, respectively. EPO exerts antiapoptotic, proliferative, antiinflammatory, and angiogenic effects within the islets. Using beta-cell-specific EPO receptor and JAK2 knockout mice, we show that these effects of EPO result from direct biological effects on beta cells and that JAK2 is an essential intracellular mediator. Thus, promotion of EPO signaling in beta cells may be a novel therapeutic strategy for diabetes prevention and treatment. |
